Diurnal Variation of Plasminogen Activator Inhibitor-1
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
To determine if nighttime administration of an aldosterone antagonist would effectively lower
peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning
administration.